TCGA-GV-A3QI-01A-11R-A220-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 36.4651774
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.430
- OXIDATIVE_PHOSPHORYLATION+0.230
- FATTY_ACID_METABOLISM+0.220
- MITOTIC_SPINDLE+0.200
- PANCREAS_BETA_CELLS+0.180
- SPERMATOGENESIS+0.180
- DNA_REPAIR+0.150
- HEME_METABOLISM+0.100
- PROTEIN_SECRETION+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.610
- TNFA_SIGNALING_VIA_NFKB-0.510
- INFLAMMATORY_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.460
- COAGULATION-0.450
- ANGIOGENESIS-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- INTERFERON_ALPHA_RESPONSE-0.400
- COMPLEMENT-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20040104.LumB | — | B | 0.917 |
| 2 | SRR23303743 | — | — | 0.912 |
| 3 | SRR1516065 | — | — | 0.909 |
| 4 | SRR35579806 | — | B | 0.905 |
| 5 | SRR1797279 | — | cohortSC | 0.902 |
| 6 | BS_EFE4YEK3 | Med | Medulloblastoma | 0.897 |
| 7 | SRR1797277 | — | cohortSC | 0.894 |
| 8 | TCGA-GU-A42P-01A-11R-A23W-07 | — | — | 0.893 |
| 9 | R320 | — | — | 0.885 |
| 10 | SRR1797245 | — | cohortSC | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |